0001415889-24-003478.txt : 20240213
0001415889-24-003478.hdr.sgml : 20240213
20240213091102
ACCESSION NUMBER: 0001415889-24-003478
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240211
FILED AS OF DATE: 20240213
DATE AS OF CHANGE: 20240213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Yea Christopher
CENTRAL INDEX KEY: 0001691102
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 24622866
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE, BUILDING 200
STREET 2: SUITE 2203
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 200915291
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (857) 999-0075
MAIL ADDRESS:
STREET 1: 55 CAMBRIDGE PARKWAY
STREET 2: SUITE 901E
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
4
1
form4-02132024_020256.xml
X0508
4
2024-02-11
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001691102
Yea Christopher
C/O KALVISTA PHARMACEUTICALS, INC
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE
MA
02142
false
true
false
false
CHIEF DEVELOPMENT OFFICER
0
Common Stock
2024-02-11
4
A
0
60000
A
106046
D
Performance Stock Units
2024-02-11
4
A
0
29167
0
A
Common Stock
29167
29167
D
Shares earned upon the vesting of a percentage of the performance stock units ("PSUs") granted to the Reporting Person on March 11, 2022. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of performance data metric goals ("Performance Metrics"). 100% of the total number of shares subject to the PSUs vested on February 11, 2024, upon Performance Metrics achieved.
Each PSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on January 10, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Metrics. 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of February 17, 2024, upon Performance Metrics achieved, subject to continued service through each vesting date.
/s/ Benjamin L. Palleiko, Attorney-in-Fact
2024-02-13